Table 1.
Baseline Participant Characteristics
| Characteristics | Overalla n = 415 | 3TC/ZDV+EFV n = 245 | FTC/TDF+EFV n = 170 | p |
|---|---|---|---|---|
| Age, years (median, IQR) | 35 (29–43) | 35 (29–43) | 35 (29–44) | .52 |
| Male | 239 (57.6) | 141 (57.6) | 98 (57.7) | .98 |
| Female | 176 (42.4) | 104 (42.4) | 72 (42.3) | |
| Race | ||||
| White | 97 (23.4) | 70 (28.6) | 27 (15.9) | .01 |
| Black | 247 (59.5) | 134 (54.7) | 113 (66.5) | |
| Other | 71 (17.1) | 41 (16.7) | 30 (17.6) | |
| Region | ||||
| United States | 71 (17.1) | 39 (15.9) | 32 (18.8) | .16 |
| Africa (Malawi, South Africa) | 128 (30.8) | 69 (28.2) | 59 (34.7) | |
| South American/Caribbean (Brazil, Peru, Haiti) | 216 (52.1) | 137 (55.9) | 79 (46.5) | |
| BMI (kg/m2) | 23.2 (20.8–26.1) | 23.4 (20.8–26.0) | 22.9 (20.8–26.3) | .36 |
| WHR | 0.88 (0.83–0.92) | 0.88 (0.83–0.93) | 0.88 (0.83–0.92) | .97 |
| CD4+ count (cells/μl) | 168 (84–233) | 172 (89–244) | 164 (83–220) | .35 |
| HIV-1 RNA (log10 copies/ml) | 5.03 (4.64–5.47) | 5.05 (4.65–5.48) | 5.02 (4.61–5.44) | .83 |
| Albumin (g/dl) | 4.0 (3.6–4.3) | 4.0 (3.6–4.3) | 4.0 (3.6–4.3) | .46 |
a
Results presented as n (frequency) or median (intraquartile range).
BMI, body mass index; EFV, efavirenz; FTC, emtricitabine; IQR, intraquartile range; 3TC, lamivudine; TDF, tenofovir; ZDV, zidovudine; WHR, waist–hip ratio.